Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUVASTRAT: Tuvusertib in Recurrent IDH Mutant Astrocytoma With ATRX Mutation
NCT07417761Phase 2Recruiting
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tuvusertib in astrocytoma, sponsored by Grupo Español de Investigación en Neurooncología. Started Dec 2025; status: recruiting.
02
Drugs
tuvusertib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NCT07417761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417761.